Author： Norman Peter
Publisher： Informa Healthcare
ISSN： 1354-3776
Source： Expert Opinion on Therapeutic Patents, Vol.18, Iss.7, 2008-07, pp. : 805-809
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Inhibition of Inflammation by a p38 MAP Kinase Targeted Cell Permeable Peptide
Medicinal Chemistry, Vol. 4, Iss. 6, 2008-11 ,pp. :
Access to resources
Recommend
By Hanson G.J.
Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 7, 1997-07 ,pp. :
p38 Inhibitors: beyond pyridinylimidazoles
By Dominguez Celia Tamayo Nuria Zhang Dawei
Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 7, 2005-07 ,pp. :
Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 1, 2000-01 ,pp. :
Allosteric p38 kinase inhibitors
By Norman Peter
Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 10, 2006-10 ,pp. :